Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Reduced‐Dose Dabrafenib–Trametinib for BRAF V600E–Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2
Saved in:
| Published in: | Respirology Case Reports |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Reduced‐Dose Dabrafenib–Trametinib for BRAF V600E–Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2
- Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
- DLGAP5 Drives Lung Adenocarcinoma Cell Growth by Promoting Autophagy Activity
- Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
- Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature Review
- Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report
- An unusual case of focal seizures after a therapeutic dose of isoniazid: a case report